Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The derived test results help the doctors in deciding the further steps in the treatment of the patient suffering from cancer. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the enrichment of the samples using different techniques, such as Next generation Sequencing (NGS), and Polymerase Chain Reaction (PCR), to detect the mutations known to cause cancer.
Liquid Biopsy Market: Key Players
The research study includes profiles of leading companies operating in the global liquid biopsy market. Key players profiled in the report include: QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories Inc., Myriad Genetics, Menarini Silicon Biosystems, Genomic Health, Thermo Fisher Scientific Inc., Illumina, Biocept & Trovagene.
Roche Diagnostics (Switzerland), launched AVENIO circulating tumor DNA (ctDNA) Analysis Kits. The kits include all reagents, bioinformatics and software to make ctDNA testing accessible to all NGS laboratories.
Drivers for the Global Liquid Biopsy Market:
The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D. Moreover, the increasing prevalence of cancer cases is playing a major role in the growth of the liquid biopsy market. The Americas is the major contributor in the liquid biopsy market partly due to the prevalence of cancer treatment and its research as well as the rising older population in the Americas. The rising older population is playing a key role in the increased adoption of liquid biopsy tests.
Opportunities for the Global Liquid Biopsy Market:
The growing demand for noninvasive and easy sample collection and the faster diagnosis of cancer is witnessed to augment the growth of the liquid biopsy market during forecasted period. With huge investments and growing evidence of the uses/applications of liquid biopsy, companies are increasingly looking to move into the liquid biopsy market. The market is witnessing a surge in the number of inorganic developments such as partnerships, collaboration, agreements, mergers, and acquisitions. Companies are focusing on inorganic strategies primarily to obtain access to innovative technologies of other players. Companies are also teaming up with universities and cancer institutes to gain robust R&D expertise.
Restrains for the Global Liquid Biopsy Market:
Increased regulations on LDTs by the FDA slower the growth of the molecular diagnostics industry as well as liquid biopsy technologies. This is also likely to increase the costs associated with introducing new tests and delay their introduction in the market. Besides regulatory challenges, reimbursement challenges also exist in the liquid biopsy market. Owing to the lack of desired sensitivity and specificity, physicians and laboratories cannot fully rely on liquid biopsies and have to use tissue biopsies in conjugation with liquid biopsies for diagnosing cancer. This factor is likely to restrain the growth of the market.
Region Wise, Global Liquid Biopsy Market Analysis:
Report covers the region wise analysis, global Liquid biopsy market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, North America leads the global Liquid biopsy market share followed by Asia Pacific & Europe. While the North America leads the global Liquid biopsy market due to the rising older population in the Americas. The rising older population is playing a key role in the increased adoption of liquid biopsy tests. While Growing demand for non-invasive treatment, rising incidence of cancer, and improving healthcare infrastructure are driving the growth of the liquid biopsy market.
Global Liquid Biopsy Market: Product analysis
- Assay kits
Global Liquid Biopsy Market: Application analysis
- Reference Laboratories
- Hospitals and Physician Laboratories
- Academic and Research Centers
Global Liquid Biopsy Market: Region analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of L.A.
- Middle East and Africa
- South Africa
- Rest of Middle East
Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialist with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever new fun research methods developed by our team.
1st Floor, Harikrishna Building,
Samarth Nagar, New Sanghvi,
Pune- 411027 India
Tel: +91-8149441100 (GMT Office Hours)
Email: [email protected]